Navigation Links
Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Date:11/16/2010

BASKING RIDGE, N.J., Nov. 16, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, Ph.D., Duke University Medical Center, presented an abstract at the AHA Scientific Sessions meeting on November 16, 2010 at 10:45 a.m. CST in Chicago, IL.

The abstract, entitled "RB006, a Direct Factor IX Inhibitor Results in Consistent and Near Complete Inhibition of Factor IX in Patients with Acute Coronary Syndromes: A RADAR Pharmacokinetic and Pharmacodynamic Substudy," evaluated the appropriateness of the selected dose of pegnivacogin (a.k.a. RB006) for use in patients with Acute Coronary Syndromes.  RB006 is part of the REG1 anticoagulation system.

Regado's ongoing Phase 2b clinical trial titled: "Randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-Ranging Study Assessing the Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome," (a.k.a. RADAR) is a partially blinded study currently enrolling 800 patients in more than 90 centers worldwide.  Patients were randomly allocated [4:1] to receive open-label RB006 or unfractionated heparin prior to catheterization and underwent various levels of double blind reversal at the end of the procedure.  This substudy, conducted in the open label portion of RADAR, included thirty patients, 20 of whom had not received recent unfractionated heparin.  It assessed PK/PD measurements just prior to and 10 minutes after dosing with RB006.  PK/PD assessments were also made, both prior to and after cardiac catheterization and before blinded dosing of anivamersen (a.k.a. RB007), RB006's complementary active control agent.  The objective was to evaluate the appropriateness of the selected RB006 dose.  
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
2. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
3. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
4. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
5. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
6. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
7. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
10. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
11. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ ... in the commercial development of the company,s supplemental ... Smart Oxygen device, being developed by ieCrowd,s subsidiary ... a patient,s changing demand for oxygen based on ... 510 (k) submission for the Smart Oxygen device ...
(Date:8/27/2015)... Pa. , Aug. 27, 2015  Now that ... the Da Vinci S™ surgical robot, hospitals with robotic ... plans. They also need to see where they stand ... on the right patients? Have they adopted best practices ... surgery program in the future? ECRI Institute, ...
(Date:8/27/2015)... MARIETTA, Ga. , Aug. 27, 2015  MiMedx ... regenerative medicine company utilizing human amniotic tissue and ... and therapies for the Wound Care, Surgical, Orthopedic, ... healthcare, responded today and corrected the multiple inaccuracies ... Transplant Foundation ("MTF") regarding the recent rulings from ...
Breaking Medicine Technology:Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4
... Lasers, a global developer, manufacturer and provider of laser, ... applications, announced today that it will launch a nationwide ... Breast Cancer Awareness Month.  The Declare Your Freedom program ... month of October 2011. Radiation therapists ...
... Oct. 5, 2011 Hill-Rom Holdings, Inc. (NYSE: ... and 2012 financial guidance on Wednesday, October 26, 2011.  You ... on Thursday, October 27, 2011, at 8 a.m. ET. ... Earnings and 2012 Financial Guidance release will be issued to ...
Cached Medicine Technology:In Honor of National Breast Cancer Awareness Month, Alma Lasers Launches Nationwide Radiation Tattoo Removal Program, Declare Your Freedom 2Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2011 Fourth Quarter Earnings and 2012 Financial Guidance Webcast 2
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted ... and improve the lives of patients, according to a newly published report. Surviving ... read the full article. , The authors of the new paper focus ...
(Date:8/29/2015)... ... 2015 , ... Brands like Toppik , Eau Thermale Avene and Bliss ... a threshold of $49.00 was required to qualify for free standard shipping,” said Jennifer ... shipping for customers regardless of the item’s selling price.” , With competitive pricing in ...
(Date:8/29/2015)... ... , ... ProDrop Particles includes over 40 particle backdrops designed for use in ... that users can shrink and stretch in the Final Cut Pro X timeline. Choose ... brightness, scale, speed, range, and flare attributes with intuitive controls found in the top-right ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... localized area with stretching, soft tissue manipulation. Platelet rich plasma injections also have ... through research to improve treatment outcomes. This localized treatment seems to address ...
(Date:8/29/2015)... TX (PRWEB) , ... August 29, 2015 , ... ... allows the company to freely market and sell Arterosil and Arterosil HP, and ... Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United ...
Breaking Medicine News(10 mins):Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... women,s risk of recurrent or new tumors by more than ... -- There,s good news for the 60 percent of ... taking the aromatase inhibitor (AI) drug letrozole (Femara) can cut ... benefit was seen even when women initiated the drug one ...
... Johnson &,Johnson will participate in the Eleventh Annual ... at the Loews Miami Beach Hotel,in Miami, Florida. ... will represent the Company in a session scheduled ... be available to investors and other interested parties,by ...
... University School of Medicine and Children,s Healthcare of Atlanta ... to find new ways to make kidney transplants more ... partner with UCLA,s Mattel Childrens Hospital in Los Angeles ... Alto for a study of kidney transplants in children. ...
... Disease Control has awarded the Indiana University School of ... of nearly $10 million in funding over 5 years ... regional entities to share data and information to enhance ... disease outbreaks and other public health emergencies. , The ...
... Two Hospitals in Central Pennsylvania Earn Designation, ... Shield is,pleased to announce the recognition of Penn ... Blue Distinction Centers for Complex and Rare,Cancers., ... of new,cancer cases each year, making it difficult ...
... March 11 Granite State Manufacturing (GSM),a ... and,commercial markets, acquired Scandia Manufacturing Company Inc. ... mechanical marine systems,for the Department of Defense. ... the United States Navy., Granite State ...
Cached Medicine News:Health News:Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer 2Health News:Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer 3Health News:NIH grant to Emory and pediatric partners aims to improve kidney transplants for children 2Health News:Regenstrief Institute tapped by CDC to combat potentially catastrophic disease outbreaks 2Health News:Highmark Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 2Health News:Highmark Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 3Health News:Granite State Manufacturing Acquires Scandia Manufacturing Company Inc. 2
... 3D Signature is a state of ... that integrates blood, sterile body fluid ... powerful microbiology workstation with comprehensive capabilities. ... identification and where expanded flexibility in ...
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid ANA II System, a microbial identification system....
IDS Rapid SS/u, a microbial identification system....
Medicine Products: